Immutep Selects 30 mg Efti as Optimal Dose After Successful AIPAC-003 Trial Completion
Immutep Ltd. announced successful completion of the AIPAC-003 Phase II trial, establishing 30 mg as the optimal dose for eftilagimod alfa in metastatic breast cancer treatment. The trial met FDA's Project Optimus requirements, showing strong response rates and immune activation. Results will be presented at the 2025 San Antonio Breast Cancer Symposium.
Immutep Ltd. has announced new data from the AIPAC-003 Phase II trial, evaluating the immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel in heavily pretreated metastatic breast cancer patients. The study resulted in strong objective response rates and immune activation, and successfully completed the FDA’s Project Optimus requirements, establishing 30 mg as the optimal biological dose for efti. The new results will be presented at the 2025 San Antonio Breast Cancer Symposium, scheduled for December 9-12, 2025. The poster presentation is available on Immutep’s website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
